TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19764973

Group type: EXPERIMENTAL
Intervention: Desmopressin treatment followed by alarm treatment after 3 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Alarm treatment followed by desmopressin after 3 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined treatment (both groups)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Normal maximum voided volume
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Small maximum voided volumes
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nocturnal polyuria
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Without nocturnal polyuria
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Relapse in group A
Number of subjects: 43
Study: 18360660

Group type: EXPERIMENTAL
Intervention: SRP + PDT (one time)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SRP + PDT (two times)
Number of subjects: 58

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 58
Study: 16202531

Group type: EXPERIMENTAL
Intervention: 75 mg S(+)‐ketamine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 50 mg S(+)‐ketamine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12952549

Group type: EXPERIMENTAL
Intervention: Mediterranean type diet (MD group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control diet (CD group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both MD and CD groups
Number of subjects: 51
Study: 10658526

Group type: EXPERIMENTAL
Intervention: BFM protocol
Number of subjects: 57

Group type: COMPARATOR
Intervention: MB protocol
Number of subjects: 57
Study: 9118580

Group type: EXPERIMENTAL
Intervention: Anteriorly placed ventilation tubes
Number of subjects: 121

Group type: COMPARATOR
Intervention: Posteriorly placed ventilation tubes
Number of subjects: 121
Study: 10149618

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncoated implants
Number of subjects: 0
Study: 6130379

Group type: EXPERIMENTAL
Intervention: Sustained-release fenfluramine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28532259

Group type: EXPERIMENTAL
Intervention: Directive intervention (20-minute session with therapist providing psychoeducation and personalized feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cultural values intervention (20-minute session with therapist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-directive intervention (20-minute session with therapist providing psychoeducation and personalized feedback)
Number of subjects: 0
Study: 28723812

Group type: EXPERIMENTAL
Intervention: Resistance training (linear periodized program)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resistance training (daily undulating periodized program)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 26888911

Group type: EXPERIMENTAL
Intervention: ART for 48 weeks in CHI
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ART for 48 weeks in PHI
Number of subjects: 52
Study: 24526542

Group type: EXPERIMENTAL
Intervention: CSD skills training (lectures, deliberate practice, and self-study)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 56
Study: 22067724

Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 6 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 20518934

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 17
Study: 18041081

Group type: EXPERIMENTAL
Intervention: 75 mg AZLI administered BID for 14 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 225 mg AZLI administered BID for 14 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15921379

Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilized peripheral blood progenitor cells (PBPC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 350
Study: 12898882

Group type: EXPERIMENTAL
Intervention: Radiological examination after surgical treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Radiological examination
Number of subjects: 38
Study: 10575073

Group type: EXPERIMENTAL
Intervention: Self-selected walking speed
Number of subjects: 27

Group type: COMPARATOR
Intervention: Slow walking speed (60% of self-selected)
Number of subjects: 27
Study: 9019842

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMH) in a single daily dose of 25000 U
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-fractionated heparin (NFH) in twice daily dose of 12500 U
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High doses of low-molecular-weight heparin (LFH)
Number of subjects: 99
Study: 1874236

Group type: EXPERIMENTAL
Intervention: Iron supplement (160 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6753454

Group type: EXPERIMENTAL
Intervention: Prospective HLA‐A and ‐B matching
Number of subjects: 159
Study: 29471861

Group type: EXPERIMENTAL
Intervention: FITNET-NHS (online CBT)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Activity Management (delivered via video call)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: FITNET-NHS
Number of subjects: 734
Study: 27842564

Group type: EXPERIMENTAL
Intervention: Heel prevention boot
Number of subjects: 183
Study: 24717370

Group type: EXPERIMENTAL
Intervention: SFA-rich diet (17:11:4; n = 65)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (9:19:4; n = 64)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich diet (9:13:10; n = 66)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 195
Study: 22505702

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + placebo
Number of subjects: 444

Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 444
Study: 20943111

Group type: EXPERIMENTAL
Intervention: VAC therapy (10 days pre-treatment with VAC dressings)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline gauzes (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 100
Study: 18439502

Group type: EXPERIMENTAL
Intervention: Local cervical anesthesia
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined cervical and intrauterine anesthesia
Number of subjects: 82
Study: 16419567

Group type: EXPERIMENTAL
Intervention: Visual evoked potentials (VEP) in patients with migraine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Visual evoked potentials (VEP) in patients with tension-type headache (TTH)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Visual evoked potentials (VEP) in healthy control group
Number of subjects: 90
Study: 12907892

Group type: EXPERIMENTAL
Intervention: Nodal mini micrometastases detected by immunohistochemical staining
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Nuclear and histologic grades
Number of subjects: 399
Study: 10494522

Group type: EXPERIMENTAL
Intervention: Compression Bandaging (CB)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Compression Bandaging + Manual Lymph Drainage (CB + MLD)
Number of subjects: 38
Study: 8724706

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: C31G
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 1931406

Group type: EXPERIMENTAL
Intervention: 5% isoflurane in oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% isoflurane and nitrous oxide in oxygen
Number of subjects: 40
Study: 6802937

Group type: EXPERIMENTAL
Intervention: Mannitol (1.4 gm/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mannitol plus furosemide (0.3 mg/kg)
Number of subjects: 22
Study: 31985629

Group type: EXPERIMENTAL
Intervention: Calf-length sequential compression devices
Number of subjects: 50

Group type: COMPARATOR
Intervention: No sequential compression devices
Number of subjects: 50
Study: 30778715

Group type: EXPERIMENTAL
Intervention: Oncology nurse phone calls (AMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-AMA (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oncology nurse interventions (AMA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RDI < 80%
Number of subjects: 60
Study: 30365588

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg SC twice weekly for 12 weeks, then 50 mg SC once weekly for an additional 12 weeks
Number of subjects: 80
Study: 25842991

Group type: COMPARATOR
Intervention: Dorsal slit incision technique (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double incision (sleeve) technique (Group B)
Number of subjects: 60
Study: 23998556

Group type: EXPERIMENTAL
Intervention: Extended assisted ventilation (EAV)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard treatment regime
Number of subjects: 283
Study: 21865366

Group type: EXPERIMENTAL
Intervention: L-T(3)
Number of subjects: 14

Group type: COMPARATOR
Intervention: L-T(4)
Number of subjects: 14
Study: 19903335

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16932963

Group type: EXPERIMENTAL
Intervention: Combination therapy (ICS plus long-acting beta2 agonist)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Single ICS
Number of subjects: 43
Study: 14665875

Group type: EXPERIMENTAL
Intervention: 12 core transperineal biopsy
Number of subjects: 214

Group type: COMPARATOR
Intervention: 6 core transperineal biopsy
Number of subjects: 214
Study: 11524643

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors (various studies)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin (PRISM-PLUS study)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Integrilin therapy (PURSUIT trial)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tirofiban alone (PRISM-PLUS study)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Least harmful treatment arm (GUSTO‐IV trial)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combined studies using a random effects model
Number of subjects: 4
Study: 9458423

Group type: EXPERIMENTAL
Intervention: Linsidomine (1 mg.h‐1 on average)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (2.5 mg.h‐1 on average)
Number of subjects: 568
Study: 7557370

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 35

Group type: COMPARATOR
Intervention: X-ray
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Flexible rhinoscopy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nasal smears for polymorphonuclear cells and eosinophils
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Other laboratory tests (CBC, sedimentation rate, quantitative immunoglobulins, total IgEs)
Number of subjects: 35
Study: 2693029

Group type: EXPERIMENTAL
Intervention: porcine glucose-dependent insulinotropic polypeptide (GIP) (0.75 pmol/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: control solution (CS)
Number of subjects: 6
Study: 793286

Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 14

Group type: COMPARATOR
Intervention: methohexitone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 14
Study: 31175096

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to cisplatin and pemetrexed (PCB)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed (PC)
Number of subjects: 448
Study: 26046499

Group type: EXPERIMENTAL
Intervention: VR rehabilitation plus conventional OT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional OT alone
Number of subjects: 35
Study: 22751218

Group type: EXPERIMENTAL
Intervention: Transverse and diagonal pelvic belt configurations (50 N force)
Number of subjects: 20
Study: 21484033

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 10
Study: 19083444

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 28
Study: 16413056

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human interleukin 11 (rhIL-11) at 50 microg/kg/day and granulocyte-macrophage colony stimulating factor (GM-CSF) at 250 microg/kg/day administered from day 11 until recovery.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human interleukin 11 (rhIL-11) and GM-CSF as supportive care after chemotherapy.
Number of subjects: 34
Study: 12831635

Group type: EXPERIMENTAL
Intervention: Insulin antibodies levels after severe hypoglycemia
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Insulin antibodies levels before severe hypoglycemia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group insulin antibodies levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of IA levels before and after severe hypoglycemia
Number of subjects: 33
Study: 10832727

Group type: EXPERIMENTAL
Intervention: Preterm group (n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Full-term group (n = 8)
Number of subjects: 19
Study: 8638169

Group type: EXPERIMENTAL
Intervention: Laser therapy at specific stages of progression of retinopathy
Number of subjects: 0
Study: 1630657

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg orally, t.i.d. for 7 consecutive days)
Number of subjects: 7
Study: 6149490

Group type: EXPERIMENTAL
Intervention: Bethanechol chloride infusion (0.05 to 0.7 mg/day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Single‐blind saline placebo infusions
Number of subjects: 4
Study: 30696270

Group type: EXPERIMENTAL
Intervention: Adapted ICBT for at-risk patients (N=51)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Standard ICBT for at-risk patients (N=51)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Not at risk patients (N=149)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Adapted ICBT for at-risk patients
Number of subjects: 251
Study: 29029797

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 300
Study: 27887601

Group type: EXPERIMENTAL
Intervention: Electrical stimulations (0.5Hz‐5Hz, bipolar, square wave, pulse width 1 ms) applied using a custom‐made transurethral catheter at different locations of the lower urinary tract
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electrical stimulations at different locations of the lower urinary tract
Number of subjects: 90
Study: 24212061

Group type: EXPERIMENTAL
Intervention: Early intervention practices using academic detailing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Delayed intervention practices
Number of subjects: 66
Study: 23705345

Group type: EXPERIMENTAL
Intervention: Group songwriting session
Number of subjects: 99

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 99
Study: 21055588

Group type: EXPERIMENTAL
Intervention: En-masse retraction
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2-step retraction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both treatment groups pooled
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Younger adolescents
Number of subjects: 64
Study: 17991659

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (30 mg/d for 8 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 15769499

Group type: EXPERIMENTAL
Intervention: Audiovisual presentation mode
Number of subjects: 64

Group type: COMPARATOR
Intervention: Audio-only presentation mode
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Increasing frequency of stuttering
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Five theme clusters of comments
Number of subjects: 64
Study: 12489064

Group type: EXPERIMENTAL
Intervention: Diet with 22.9% of energy from saturated fat
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diet with 9.3% of energy from saturated fat replaced by trans fat
Number of subjects: 32
Study: 9624555

Group type: EXPERIMENTAL
Intervention: amikacin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ofloxacin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: minocycline
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: piperacillin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: cefotiam
Number of subjects: 55
Study: 7714306

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonresponse
Number of subjects: 44
Study: 2109432

Group type: EXPERIMENTAL
Intervention: Lactinex (culture of L. acidophilus and L. bulgaricus), administered four times a day for ten days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered four times a day for ten days
Number of subjects: 0
Study: 390810

Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Estracyt)
Number of subjects: 107
Study: 31847572

Group type: EXPERIMENTAL
Intervention: Viewing normal weight individuals engaging in vigorous exercise
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Viewing overweight/obese individuals engaging in vigorous exercise
Number of subjects: 102

Group type: COMPARATOR
Intervention: No-exercise video with participants of various weight statuses (control condition)
Number of subjects: 102
Study: 31161722

Group type: EXPERIMENTAL
Intervention: Educational program based on Roy's adaptation model for 4 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 27248848

Group type: EXPERIMENTAL
Intervention: Continuous Ultrasonic Irrigation (CUI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Syringe Irrigation (SI)
Number of subjects: 70
Study: 25994442

Group type: EXPERIMENTAL
Intervention: Urine F2‐isoprostanes at the end of surgery
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Urine isofurans at the end of surgery
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Urine F3‐isoprostanes at the end of surgery
Number of subjects: 551
Study: 23625485

Group type: EXPERIMENTAL
Intervention: Tricuspid valve detachment (TVD) for VSD closure
Number of subjects: 35

Group type: COMPARATOR
Intervention: Closure without tricuspid valve detachment (control)
Number of subjects: 35
Study: 21304923

Group type: EXPERIMENTAL
Intervention: IPTc with sulphadoxine pyrimethamine (SP) plus amodiaquine (AQ)
Number of subjects: 3017
Study: 19211603

Group type: EXPERIMENTAL
Intervention: Atropine 1%
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 16769273

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional clamping methods
Number of subjects: 60
Study: 14742400

Group type: EXPERIMENTAL
Intervention: Music played during surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: No music played (control group)
Number of subjects: 30
Study: 11282447

Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (0.7 g/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Alcohol-free drinks
Number of subjects: 19
Study: 9215018

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lignocaine (50 ml containing 200 mg lignocaine and 1:500,000 adrenaline)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (50 ml saline i.p.)
Number of subjects: 39
Study: 8116338

Group type: EXPERIMENTAL
Intervention: Specific cognitive treatment (20 pts) including direct training, compensatory strategies, and neuropsychotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Specific cognitive treatment (20 pts)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-specific, deliberately diffuse mental stimulation (20 pts)
Number of subjects: 40
Study: 3547053

Group type: EXPERIMENTAL
Intervention: 50 mg of elemental zinc (as 220 mg zinc sulphate), three times a day for six weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 150 mg of zinc a day
Number of subjects: 47
Study: 30029621

Group type: EXPERIMENTAL
Intervention: ILM peeling (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inverted ILM flap (Group B)
Number of subjects: 60
Study: 28401310

Group type: EXPERIMENTAL
Intervention: Block periodised resistance training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Daily undulating periodised resistance training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Non-periodised resistance training
Number of subjects: 41

Group type: COMPARATOR
Intervention: All training groups (BP, DUP, NP)
Number of subjects: 41
Study: 26553211

Group type: COMPARATOR
Intervention: Unblinded tracking
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Smart texts
Number of subjects: 48
Study: 23751738

Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair (EVAR); surgical success rate 100%, perioperative mortality rate 0.8%, mean operative duration 150 min, mean blood loss 140 ml, mean hospitalization time 15.5 days, mean hospitalization cost RMB 104,800; stent graft patency 96% (120 cases), 10 deaths, 8 complications (5.6%).
Number of subjects: 218

Group type: COMPARATOR
Intervention: Open surgery; surgical success rate 98.8%, perioperative mortality rate 2.3%, mean operative duration 230 min, mean blood loss 450 ml, mean hospitalization time 30 ± 3 days, mean hospitalization cost RMB 58,000; stent graft patency 98.8% (79 cases), 8 deaths (10%).
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Comparison of long-term effects between EVAR and open surgery;
Number of subjects: 218
Study: 20734238

Group type: EXPERIMENTAL
Intervention: Legume enriched diet (1.5 servings/1,000 kcal), high fiber (21 g/1,000 kcal), low GI (GI = 38)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy American diet (no legume consumption, fiber consumption = 9 g/1,000 kcal, GI = 69)
Number of subjects: 64
Study: 18565239

Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg and 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine (IR 2 mg bd/ER 4 mg)
Number of subjects: 0